Treating hepatitis C virus in patients with chronic renal failure

Affiliations

¹ Department of Internal Medicine II, Martin-Luther-University Halle Wittenberg, Halle (Saale), D06120, Germany. Electronic address: matthias.girndt@medizin.uni-halle.de.

Comment

Matthias Girndt. Lancet Gastroenterol Hepatol. 2017 Aug.

. 2017 Aug;2(8):544-546.

doi: 10.1016/S2468-1253(17)30183-8.

¹ Department of Internal Medicine II, Martin-Luther-University Halle Wittenberg, Halle (Saale), D06120, Germany. Electronic address: matthias.girndt@medizin.uni-halle.de.

No abstract available

Comment on

Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
Bruchfeld A, Roth D, Martin P, Nelson DR, Pol S, Londoño MC, Monsour H Jr, Silva M, Hwang P, Arduino JM, Robertson M, Nguyen BY, Wahl J, Barr E, Greaves W. Bruchfeld A, et al. Lancet Gastroenterol Hepatol. 2017 Aug;2(8):585-594. doi: 10.1016/S2468-1253(17)30116-4. Epub 2017 May 30. Lancet Gastroenterol Hepatol. 2017. PMID: 28576451 Clinical Trial.